多发性骨髓瘤免疫逃逸机制研究进展  

Research progress on immune evasion mechanism of multiple myeloma

作　　者：梅舒翀 余莉[2] 陈国安(指导)[3] MEI Shu-Chong;YU Li;CHEN Guo-An(Emergency Department of the Second Affiliated Hospital of Nanchang University,Nanchang 330006,China)

机构地区：[1]南昌大学第二附属医院急诊科,南昌330006 [2]南昌大学第二附属医院血液内科,南昌330006 [3]南昌大学第一附属医院血液科,南昌330006

出　　处：《中国免疫学杂志》2020年第21期2677-2680,共4页Chinese Journal of Immunology

基　　金：江西省卫计委科技计划(20181097)资助。

摘　　要：机体免疫系统通过特异性和非特异性途径对肿瘤细胞进行免疫监视和杀伤,肿瘤免疫逃逸是肿瘤出现耐药和复发的重要原因之一。多发性骨髓瘤(MM)是一种骨髓内异常浆细胞增多的恶性肿瘤,约占恶性肿瘤的近1%,血液系统肿瘤的10%,几乎所有患者治疗后复发,甚至导致原发耐药。MM存在免疫逃逸现象,因此,对MM如何实现免疫逃逸的研究,有助于临床上开发治愈MM的免疫治疗方案。The immune system monitors and kills tumor cells through specific and non-specific pathways,and immune evasion is one of the important reasons for drug resistance and relapse of tumor.Multiple myeloma(MM)is a malignant tumor with abnormal plasma cell proliferation in bone marrow,accounting for nearly 1%of malignant tumors and 10%of hematopoietic system tumors.Almost all patients relapsed after treatment,even primary drug resistance.MM has immune evasion,therefore,to realize the immune evasion of tumor is conductive to develop immunotherapy program for curing tumor in clinical.

关 键 词：多发性骨髓瘤 免疫逃逸 进展 

分 类 号：R559[医药卫生—血液循环系统疾病]